Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tarsus PharmaceuticalsTARS +9.07%47 Cash-to-Debt is 6.18 as of Jun. 2026, which is 28% below its 10-year median of 8.59. GuruFocus rates TARS with a GF Score™ of 47/100 and a GF Value™ of $159.18 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,398 Biotechnology companies, Tarsus Pharmaceuticals ranks worse than 50.5% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tarsus Pharmaceuticals's cash to debt ratio for the quarter that ended in Jun. 2026 was 6.18.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tarsus Pharmaceuticalscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Tarsus Pharmaceuticals's Cash-to-Debt or its related term are showing as below:
TARS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 4.02 Med: 8.59 Max: No Debt
Current: 6.18
During the past 8 years, Tarsus Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 4.02. And the median was 8.59.
TARS's Cash-to-Debt is ranked worse than 50.5% of 1398
companies
in the Biotechnology industry
Industry Median: 6.575
vs TARS: 6.18
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Tarsus Pharmaceuticals Cash-to-Debt Related Terms
Tarsus Pharmaceuticals Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (TARS) has a Cash-to-Debt of 6.18 as of Jun. 2026. This is 28% below median its historical median of 8.59. Over the past decade, Tarsus Pharmaceuticals' Cash-to-Debt has ranged from 4.02 to 10,000.00. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #706 out of 1398 companies in the Biotechnology industry, placing it in the top 50.5%.
Is Tarsus Pharmaceuticals' Cash-to-Debt too high?
Tarsus Pharmaceuticals' current Cash-to-Debt of 6.18 is 28% below median its 10-year median of 8.59. Over the past 10 years, this metric has ranged from a low of 4.02 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.58. Tarsus Pharmaceuticals' value of 6.18 is 6% below this industry median. Based on the distribution chart, Tarsus Pharmaceuticals ranks #706 out of 1398 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tarsus Pharmaceuticals has a GF Score™ of 47/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Cash-to-Debt compare to IMNM and NAMS?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #706 out of 1398 companies for Cash-to-Debt. This places Tarsus Pharmaceuticals in the lower half of its industry. The industry median Cash-to-Debt is 6.58. Tarsus Pharmaceuticals' value of 6.18 is 6% below this benchmark. Historically, Tarsus Pharmaceuticals' own Cash-to-Debt has ranged from 4.02 to 10,000.00 over the past decade. While the company's 10-year median is 8.59 vs. the industry median of 6.58, Tarsus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.58, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsus Pharmaceuticals's current Cash-to-Debt of 6.18 is 6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current Cash-to-Debt is 6.18, which is 28% below median its own 10-year median of 8.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Significantly Undervalued. The stock's GF Value™ is $159.18, compared to a current price of $90.78 — trading 43% below its estimated fair value. The current Cash-to-Debt is 6.18, which is 28% below median its 10-year median of 8.59 and 6% below the Biotechnology industry median of 6.58. Tarsus Pharmaceuticals' overall GF Score™ is 47/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Cash-to-Debt is 6.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $90.78 is trading 43% below its estimated GF Value™ of $159.18.
GuruFocus considers Tarsus Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for TARS:
Cash-to-Debt: 6.18 (28% below median its 10-year median of 8.59)
GF Value™: $159.18 vs. price of $90.78 (43% below fair value)
Industry Position: 6% below the Biotechnology median (#706 of 1398)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
47GF Score
Get the complete analysis for TARS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
